Photo of Jeffrey A. Gelfand,  MD

Jeffrey A. Gelfand, MD

Massachusetts General Hospital

Massachusetts General Hospital
Phone: (617) 726-1796
Fax: (617) 726-7416


jgelfand@partners.org

Jeffrey A. Gelfand, MD

Massachusetts General Hospital

EDUCATIONAL TITLES

  • Professor, Medicine, Harvard Medical School
  • Physician, Infectious Disease Unit, Massachusetts General Hospital

DF/HCC PROGRAM AFFILIATION

Research Abstract

We have developed a novel approach for targeting (tumor) antigens whose sequence may not be known or structure even identified. We have linked scFV's to MycobacteriumTb HeatShockProtein 70, thus developing a novel fusion protein vaccine for presenting antigen to APCs in order to generate both a CD-4 and CD -8 response. The scFV’s can be selected for their binding to an uncharacterized antigen or to a characterized antigen by binding studies, and the appropriate V-genes can then be selected. The scFV genes are fused to the gene for MTb HSP 70, and the new fusion gene is expressed as the fusion protein in E. coli. We have succeeded in generating a fusion vaccine targeting Folate Receptor-alpha, hyper-expressed in ovarian and many breast tumors.

Publications

Powered by Harvard Catalyst
  • Brauns T, Leblanc P, Gelfand JA, Poznanski M. Could mycobacterial Hsp70-containing fusion protein lead the way to an affordable therapeutic cancer vaccine? 2015; 14:435-46. PubMed
  • Leblanc P, Moise L, Luza C, Chantaralawan K, Lezeau L, Yuan J, Field M, Richer D, Boyle C, Martin WD, Fishman JB, Berg EA, Baker D, Zeigler B, Mais DE, Taylor W, Coleman R, Warren HS, Gelfand JA, De Groot AS, Brauns T, Poznansky MC. VaxCelerate II: rapid development of a self-assembling vaccine for Lassa fever. Hum Vaccin Immunother 2015; 10:3022-38. PubMed
  • Chen X, Kim P, Farinelli B, Doukas A, Yun SH, Gelfand JA, Anderson RR, Wu MX. A novel laser vaccine adjuvant increases the motility of antigen presenting cells. PLoS ONE 2010; 5:e13776. PubMed